Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prognostic Value of Inflammatory Markers for Postoperative Complications in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

NCT03218449 is registered in ClinicalTrials.gov with Gangnam Severance Hospital as lead sponsor.

NCT NCT03218449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03218449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prognostic Value of Inflammatory Markers for Postoperative Complications in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Lead sponsor
Gangnam Severance Hospital
Phase
Observational
Overall status
Unknown status
Start date
June 13, 2017
Completion date
November 30, 2017
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytoreductive surgery with hyperthermic intraperitoneal chemotherapy